Saturday, May 14
6:45 - 9 am
(MOCS) Maintenance of Certification (MOC) Learning Session
Glen Lew, MD (moderator); Greg Armstrong, MD; Smita Bhatia, MD MPH; Leonardo R. Brandao, MD MSC; Sharon Castellino, MD MSc; Michael DeBaun, MD; Shannon Maude, MD PhD; Guy Young, MD; Robert Liem, MD; Angela Smith, MD
The Maintenance of Certification (MOC) learning session will feature an American Board of Pediatrics (ABP) Lifelong Learning and Self-Assessment Module. It is intended not only for those who are enrolled in the MOC process and would like to earn MOC activity points, but also for anyone wishing for a broad review of recent literature relevant to pediatric hematology/oncology. The session will be conducted in an interactive group setting led by authors or experts in their fields. The session will cover multiple-choice questions in the 2016 Pediatric Hematology-Oncology Self-Assessment. Please bring your laptop to enter the answers to each question during the session. At the completion of this session, those enrolled in the ABP MOC program will have been able to submit their answers to ABP MOC for scoring to receive 10 MOC Part 2 points and 3 AMA PRA Category 1 Credits(tm). Enrolled participants can access the module(s) online from the ABP website at www.abp.org. At the conclusion of the session, participants will transfer the answers to their online module and submit the module to ABP for scoring. For additional information about ABP’s MOC program requirements, visit www.abp.org or call the ABP Contact Center at 919.929.0461. Please note that this is not a board review activity; the workshop is designed to facilitate completion of ABP’s Lifelong Learning and Self-Assessment MOC requirement. Advance registration is required. The registration fee is $50.
(PSIG) Palliative Care Special Interest Group (SIG)
Chair: Karen Moody, MD
From Schrödinger's cat to myths, magic & methadone: Advanced pain treatment in children with serious hematologic/oncologic disease
Stefan Friedrichsdorf MD
The Pediatric Palliative Care Special Interest group is proud to announce guest speaker Stefan Friedrichsdorf MD will be providing an interactive lecture on interdisciplinary acute pain assessment and management in children with hematologic/oncologic disease. Stefan Friedrichsdorf MD is the Medical Director of the Department of Pain Medicine, Palliative Care and Integrative Medicine at Children’s Hospitals and Clinics in Minnesota and is an internationally recognized expert in pediatric pain and palliative care.
(D20) Patient and Family Engagement in Pediatric Hematology/Oncology—What Works?
Moderator: Janice F. Olson, MD MHA
Patient engagement tops many healthcare executives’ “to-do” list. Why the clamor? By increasing patients’ knowledge, skills, abilities, and willingness to adopt positive behaviors, we anticipate improvements in patient education, satisfaction, and safety—three reimbursement determinants in value-based care—as well as in clinical outcomes. We will explore opportunities, barriers, and risks for technologic and operational approaches to enhancing patient engagement. After attending this session, participants should understand the benefits of an engaged patient population, identify strategies to harness patients’ motivation to be well, and visualize patient reported outcomes aligning with their values.
Introduction and Literature Review
Christopher E. Dandoy, MD MSC
Point-Counterpoint: Patients' vs. Clinicians' Definitions of Engagement—One Size Does Not Fit All
Terrie Flatt, DO MA; Mireya P. Velasquez, MD
Engaging Patients—Why Does IT Think They Own It and What Are They Doing About It?
Eric J. Werner, MD MMM
(D21) Advances in the Management of Pediatric Thyroid Cancer
Moderator: Rajkumar Venkatramani, MD MS MRCPCH
The incidence of pediatric thyroid cancer is increasing and it accounts for 11% of all malignancies in 15- to 19-year-olds. The American Thyroid Association released guidelines for the treatment of pediatric thyroid cancer in 2015. Multiple targeted agents (e.g., sorafenib, vandetanib, cabozantinib) were recently approved for thyroid cancers. Pediatric oncologists frequently encounter patients with thyroid nodules, and are increasingly asked to manage patients with refractory tumors. This workshop will review the latest advances in thyroid cancer treatment and define the role of pediatric oncologist in the care of these patients. Discussion will focus on real-life cases seen in pediatric oncology clinic.
Diagnostic Approach to Pediatric Thyroid Nodules
Andrew J. Bauer, MD FAAP
The American Thyroid Association Management Guidelines for Pediatric Thyroid Cancer
Steven G. Waguespack, MD
Role of Pediatric Oncologist in the Management of Thyroid Cancer
Rajkumar Venkatramani, MD MS MRCPCH
(D22) Preparing a Successful Mentored Career Grant Application
Moderator: Mona D. Shah, MD
This session is intended to guide early-career members in their career development by allowing them to witness the process of grant review and evaluation. Key elements of the process as well as targeted criticism of prepared grant proposals will assist attendees in their own grant application preparation. The session also includes an interactive question and answer session for attendees to ask questions regarding specific areas of concern. Given that 85% of K awardees are unsuccessful in obtaining an R01 grant, we would like to continue this dialogue into subsequent years.
Mock Grant Review Panel
Douglas K. Graham, MD PhD; Kathleen M. Sakamoto, MD PhD; Daniel S. Wechsler, MD PhD
(PS4019-27) Concurrent Platform Sessions
(D23) Advances and Challenges in the Diagnosis of Hereditary Hemolytic and Dyserythropoietic Anemia
Moderator: Charles T. Quinn, MD MS
This workshop will address challenges encountered in the diagnosis of thalassemia, erythrocyte membrane and enzyme disorders, and congenital dyserythropoietic anemia. Rapid advances in the understanding of the genetics and pathogenesis of these disorders and the recent development and increasing availability of new clinical diagnostic methods have produced a knowledge gap among hematologists that can impact patient care. Interactive reviews of real cases will be used to educate participants about the clinical presentation and modern biochemical, rheological, and molecular methods to best diagnose these conditions. This interactive workshop will enable participants to better recognize, diagnose, and treat many causes of congenital anemia.
Genetic Testing for the Thalassemia Syndromes: A Comprehensive Approach
Charles T. Quinn, MD MS
Erythrocyte Membrane and Enzyme Disorders: When and How to Test?
Satheesh Chonat, MD
Congenital Dyserythropoietic Anemias (CDA): Diagnostic Work-Up and Development of a CDA Registry in North America
Theodosia A. Kalfa, MD PhD
Challenging Cases in Congenital Hemolytic and Dyserythropoietic Anemias
Jeffrey M. Lipton, MD PhD
(D24) End-of-Life Care for Adolescents and Young Adults (AYA) with Cancer: Opening the Door to Conversations about Care
Moderator: Jennifer Mack, MD
70,000 adolescents and young adults (AYAs) are diagnosed with cancer in the United States per year, and cancer is their leading disease-related cause of death. AYAs experience cancer during psychological and social development, factors which add complexity to end-of-life (EOL) care, but tools exist to help AYAs understand their medical situation and make care decisions that reflect their EOL wishes. This session will review the evidence base about EOL care needs and experiences among AYAs and their families. Case-based discussion will focus on eliciting EOL care preferences and making recommendations that are individualized to the preferences of AYA patients.
EOL Care Needs of AYA Cancer Patients and their Families
Abby R. Rosenberg, MD MS
Gaps and Challenges in AYA EOL Care
Jennifer Mack, MD
Advance Care Planning Tools for AYAs
Lori Wiener, PhD
(D25) Clinical Updates in Pediatric Hematologic and Oncologic Emergencies*
Moderator: Lisa Triche, MSN RN CPNP
Children with cancer are at great risk for developing life-threatening emergencies secondary to the malignancy or its treatment. Hematologic and oncologic emergencies carry significant morbidity and mortality. Advances in therapy continue to be made and may increase the incidence of life-threatening emergencies in the young patient. Newly available therapies have toxicity profiles that may not be fully understood and warrant updated review of the presentation and management of potential life-threatening events in the young patient. Providers will benefit from an updated discussion and practical approach in the management of hematologic and oncologic emergencies.
Recognizing and Treating Neurotoxicity of Novel Chemotherapeutic Agents
Zsila Sadighi, MD
Calming the Storm: Predicting, Preventing, and Treating Cytokine Release Syndrome after Novel Immunotherapies
David T. Teachey, MD
Autoimmune Hemolytic Anemias
Trinh Nguyen, DO